Chemical Synthesis Core

通常情况下，无论是需要帮助的PI或分子目标教师带来的项目的核心考虑。分子靶向学院（由病理学实验室的Patricia Steeg博士担任主席）是一个指导委员会，为CCR研究人员提供项目援助，以支持临床前开发。由分子靶向学院提出的项目通常需要重新合成或简单的药物化学，这将使该项目在发展中向前迈进。在核心同意开展项目之前，PI将项目正式提交给合成团队，以确定化学、合成可行性、成本、完成时间和替代商业/供应商选项。在PI会议之前，合成团队将已经确定拟定的合成和/或探索供应商选项。在PI会议期间，决定核心是否将承担项目或推荐替代方法。特定项目的范围是上下文相关的。有些项目只是“供雇用的综合”，而其他项目则更具协作性质，涉及共同撰写出版物。Joel Schneider积极管理项目。核心小组会议每周在弗雷德里克举行一次，讨论进展情况，解决化学问题和审查分析数据。在需要的时候，杰伊·施内克洛斯博士和马丁·施纳曼博士，最近的终身教职员工，会被咨询来制定综合战略。这两个PI在合成方法和天然产物合成方面都有特殊的培训。

Typically, either a PI in need of assistance or the Molecular Targets Faculty brings projects to the Core for consideration. The Molecular Targets Faculty (chaired by Dr. Patricia Steeg, Laboratory of Pathology) is a steering committee that provides CCR investigators with assistance in their projects to support pre-clinical development. Projects presented by the Molecular Targets Faculty are typically in need of re-synthesis or simple medicinal chemistry that will allow the project to move forward in development. Before the Core agrees to undertake the project, the PI presents the project formally to the synthesis team to define the chemistry, synthetic feasibility, cost, time-to-completion, and alternate commercial/ vendor options. Prior to the PI meeting, the synthetic team will have already determined a proposed synthesis and/or explored vendor options. During the PI meeting, a decision is made as to whether or not the Core will undertake the project or recommend an alternate approach. The scope of a particular project is contextual. Some projects are simply "synthesis for hire" and others are more collaborative in nature and involve co-authoring publications. Joel Schneider actively manages projects. Core group meetings are held in Frederick once a week to discuss progress, troubleshoot chemistry and review analytical data. When needed, Drs. Jay Schneekloth and Martin Schnermann, recent tenure track hires, are consulted to develop synthetic strategy. Both PIs have exceptional training in synthetic methodology and natural product synthesis.